Bright Green CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Bright Green Corporation has filed a proposed Chapter 11 Plan of Reorganization, seeking to restructure the company and pay creditors in full while allowing existing equity shareholders to retain their interests.
8-K: Bright Green Corp. Files for Chapter 11, Plans Restructuring and Shift to Controlled Substances
Bright Green Corporation has filed for Chapter 11 bankruptcy to implement a prepackaged restructuring plan, including a shift away from cannabis and towards the production of DEA scheduled controlled substances.
Bright Green Corporation has entered into a Restructuring Support Agreement with its major shareholder and plans to file for Chapter 11 bankruptcy to reorganize the company.
Bright Green Corporation has announced a significant restructuring, including the resignation of key executives and board members, and the appointment of Lynn Stockwell as CEO, alongside a new strategic focus on plant-based controlled substances.
Bright Green Corporation's 2024 Annual Meeting saw shareholders elect directors, approve a reverse stock split, authorize stock issuance, and ratify the accounting firm.
8-K: Bright Green Corporation Secures $2.5 Million Loan, Amends Credit Agreement with Conversion Option
Bright Green Corporation has entered into an amended credit agreement, securing a minimum of $2.5 million in new funding and providing a conversion option into preferred stock.
Bright Green Corporation amended a warrant to extend its termination date and secured a minimum $3.5 million line of credit, while also facing potential delisting from the Nasdaq.
Bright Green Corporation reports progress in its EB-5 investment program, DEA quota applications, and plans for commercial production of controlled substances.
8-K: Bright Green Corporation Amends CEO's Employment Agreement, Outlines Performance-Based Equity Awards
Bright Green Corporation has amended its executive employment agreement with CEO Gurvinder Singh, outlining new compensation terms and performance-based equity awards.
Bright Green Corporation has entered into a $60 million credit agreement and a settlement agreement resolving outstanding disputes related to previous transactions.
Bright Green Corporation has appointed Sean Deson to its Board of Directors and extended its agreement with CFO Saleem Elmasri through February 2025.
Bright Green Corporation has received final approval from the New Mexico Board of Pharmacy and the DEA to research, produce, and manufacture Schedule I and II plant-based drugs and APIs.
Bright Green Corporation has appointed its CEO to the board of directors and named a new board chair, following the resignation of the executive chairman.
Bright Green Corporation has received an extension from Nasdaq until August 12, 2024, to regain compliance with the minimum bid price rule.